The latest price target for Theravance Biopharma (NASDAQ:TBPH) was reported by HC Wainwright & Co. on September 16, 2024. The analyst firm set a price target for $15.00 expecting TBPH to rise to within 12 months (a possible 88.21% upside). 7 analyst firms have reported ratings in the last year.

The latest analyst rating for Theravance Biopharma (NASDAQ:TBPH) was provided by HC Wainwright & Co., and Theravance Biopharma reiterated their buy rating.

The last upgrade for Theravance Biopharma Inc happened on November 5, 2021 when JP Morgan raised their price target to $12. JP Morgan previously had an underweight for Theravance Biopharma Inc.

The last downgrade for Theravance Biopharma Inc happened on August 6, 2024 when Leerink Partners changed their price target from $15 to $10 for Theravance Biopharma Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Theravance Biopharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Theravance Biopharma was filed on September 16, 2024 so you should expect the next rating to be made available sometime around September 16, 2025.

While ratings are subjective and will change, the latest Theravance Biopharma (TBPH) rating was a reiterated with a price target of $15.00 to $15.00. The current price Theravance Biopharma (TBPH) is trading at is $7.97, which is out of the analyst’s predicted range.